Bayhill Therapeutics, Inc. Enters Exclusive, Worldwide Collaboration with Genentech, Inc. (DNA) (JOBS) for BHT-3021 in Type 1 Diabetes; Deal Could Potentially Exceed $350M
6/10/2009 7:22:53 AM
More...
|
Bayhill Therapeutics, Inc. Founder Lawrence Steinman, M.D. Recognized for Leadership in Multiple Sclerosis
3/16/2009 10:01:06 AM
More...
|
Bayhill Therapeutics, Inc. to Participate in Interactive Workshop at BIO-Europe Spring(R) 2009
3/12/2009 8:49:30 AM
More...
|
Bayhill Therapeutics, Inc. to Present Phase II Follow-up Data on BHT-3009 for Treatment of Multiple Sclerosis
3/9/2009 8:49:19 AM
More...
|
Bayhill Therapeutics, Inc. and The Juvenile Diabetes Research Foundation Announce Research Collaboration for the Clinical Development of a Novel Immunotherapeutic DNA Vaccine for Type 1 Diabetes
10/30/2008 10:25:25 AM
More...
|
Bayhill Therapeutics, Inc. Withdraws IPO Plans
6/30/2008 7:07:18 AM
More...
|
Bayhill Therapeutics, Inc. Presents Data From a Phase II Trial of BHT-3009 in Multiple Sclerosis at American Academy of Neurology 60th Annual Meeting
4/17/2008 10:02:56 AM
More...
|
Bayhill Therapeutics, Inc. Announces Presentation of MS Drug Candidate BHT-3009 at American Academy of Neurology 60th Annual Meeting
4/11/2008 8:59:01 AM
More...
|
Bayhill Therapeutics, Inc. Files for $86.25M IPO
1/9/2008 6:57:24 AM
More...
|
Bayhill Therapeutics, Inc. to Present Positive Data From a Phase IIb Trial of BHT-3009 in Multiple Sclerosis
10/5/2007 10:47:50 AM
More...
|
|